Literature DB >> 15077237

Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome.

Andrew H Evans1, Regina Katzenschlager, Dominic Paviour, John D O'Sullivan, Silke Appel, Andrew D Lawrence, Andrew J Lees.   

Abstract

Punding is a term that was coined originally to describe complex prolonged, purposeless, and stereotyped behaviour in chronic amphetamine users. A structured interview of 50 patients with higher dopamine replacement therapy requirements (>800 levodopa equivalent units/day) from 123 unselected patients with Parkinson's disease (PD) from a PD clinic identified 17 (14%) patients with punding. Punding was acknowledged as disruptive and unproductive by the patients themselves, but forcible attempts by family to interrupt the behaviour led to irritability and dysphoria. Punding was associated with very high doses of dopamine replacement therapy often related to a pattern of chronic inappropriate overuse of dopaminergic medication. We believe that this is an underreported, socially disabling phenomenon that is commonly associated with the syndrome of dopamine dysregulation and is phenomenologically distinct from both obsessive-compulsive disorder and mania. Copyright 2004 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15077237     DOI: 10.1002/mds.20045

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  126 in total

1.  Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale.

Authors:  Daniel Weintraub; Eugenia Mamikonyan; Kimberly Papay; Judith A Shea; Sharon X Xie; Andrew Siderowf
Journal:  Mov Disord       Date:  2011-12-01       Impact factor: 10.338

2.  Management of punding in Parkinson's disease: an open-label prospective study.

Authors:  A Fasano; L Ricciardi; M Pettorruso; A R Bentivoglio
Journal:  J Neurol       Date:  2010-11-12       Impact factor: 4.849

3.  Stereotypic behaviors in degenerative dementias.

Authors:  S Prioni; V Fetoni; F Barocco; V Redaelli; C Falcone; P Soliveri; F Tagliavini; A Scaglioni; P Caffarra; L Concari; S Gardini; F Girotti
Journal:  J Neurol       Date:  2012-05-31       Impact factor: 4.849

4.  Brain structural and functional signatures of impulsive-compulsive behaviours in Parkinson's disease.

Authors:  F Imperiale; F Agosta; E Canu; V Markovic; A Inuggi; M Jecmenica-Lukic; A Tomic; M Copetti; S Basaia; V S Kostic; M Filippi
Journal:  Mol Psychiatry       Date:  2017-03-07       Impact factor: 15.992

5.  Psychosis and concurrent impulse control disorder in Parkinson's disease: A review based on a case report.

Authors:  Bruno Fukelmann Guedes; Marcia Rubia Gonçalves; Rubens Gisbert Cury
Journal:  Dement Neuropsychol       Date:  2016 Apr-Jun

Review 6.  Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management.

Authors:  Sean S O'Sullivan; Andrew H Evans; Andrew J Lees
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 7.  Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.

Authors:  Barbara Connolly; Susan H Fox
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

8.  Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers.

Authors:  David Okai; Sally Askey-Jones; Michael Samuel; Sean S O'Sullivan; K Ray Chaudhuri; Anne Martin; Joel Mack; Richard G Brown; Anthony S David
Journal:  Neurology       Date:  2013-01-16       Impact factor: 9.910

9.  Imaging changes associated with cognitive abnormalities in Parkinson's disease.

Authors:  Yuko Koshimori; Barbara Segura; Leigh Christopher; Nancy Lobaugh; Sarah Duff-Canning; Romina Mizrahi; Clement Hamani; Anthony E Lang; Kelly Aminian; Sylvain Houle; Antonio P Strafella
Journal:  Brain Struct Funct       Date:  2014-05-13       Impact factor: 3.270

10.  Jumping to conclusions in untreated patients with Parkinson's disease.

Authors:  Flavio Henrique de Rezende Costa; Bruno Averbeck; Sean S O'Sullivan; Maurice Borges Vincent; Ana Lucia Rosso; Andrew J Lees; Atbin Djamshidian
Journal:  Neuropsychologia       Date:  2016-03-05       Impact factor: 3.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.